Discovery, lead identification and exploration of potential oxadiazole derivatives in targeting STAT3 as anti-cancer agents.

Anticancer compounds Drug discovery Kinases Oxadiazole derivatives STAT3

Journal

In silico pharmacology
ISSN: 2193-9616
Titre abrégé: In Silico Pharmacol
Pays: Germany
ID NLM: 101623954

Informations de publication

Date de publication:
2024
Historique:
received: 16 08 2024
accepted: 08 09 2024
pmc-release: 14 09 2025
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 17 9 2024
Statut: epublish

Résumé

Oxadiazoles an important heterocyclic scaffold of medicinal importance in the field of drug discovery. In the study, a library of oxadiazole based compounds was selected for screening against STAT-3 as anti-cancer target. STAT3 is a potential target of interest in cancer therapy. A total of 544 screened library of compounds was subjected to molecular docking against STAT-3 (6NJS and 6NQU). The compounds with good dock score and binding interations were further subjected to in-silico ADME analysis followed by toxicity estimation. A total of 141 hits were selected against 6NJS and 50 hits against 6NQU and further screened for kinetic properties and drug likeliness. The compounds were screened on the basis of physico-chemical properties, solubility, gastrointestinal absorption, BBB permeability, synthetic accessibility, Lipinski and other violations. Best compounds obtained after ADME analysis were further subjected for toxicity analysis. Carcinogenecity, mutagenicity, Ames and other important parameters were considered for toxicity based screening. The best leads thus obtained (compound 114 and 40) were further subjected to molecular dynamics against the respective target proteins. MD simulations were run to access the stability of C-114 and C-40 along with the dynamic behaviour of both complexes for about 100 ns and shows good stability with the proteins.

Identifiants

pubmed: 39286329
doi: 10.1007/s40203-024-00261-w
pii: 261
pmc: PMC11401806
doi:

Types de publication

Journal Article

Langues

eng

Pagination

83

Informations de copyright

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Déclaration de conflit d'intérêts

Conflict of interestThe authors declare no competing interests.

Auteurs

Vivek Panwar (V)

Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan, 173229 India.

Sounok SenGupta (S)

Department of Pharmacology, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan, 173229 India.

Saroj Kumar (S)

Department of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029 India.

Praveen P Singh (PP)

Department of Chemistry, United College of Engineering & Research, Prayagraj, 211010 India.

Arun Kumar (A)

Mahavir Cancer Sansthan & Research Centre, Patna, Bihar- 801505 India.

Shavkatjon Azizov (S)

Laboratory of Biological Active Macromolecular Systems, Institute of Bioorganic Chemistry, Academy of Sciences Uzbekistan, 100125 Tashkent, Uzbekistan.
Faculty of Life Sciences, Pharmaceutical Technical University, 100084 Tashkent, Uzbekistan.

Manoj K Gupta (MK)

Department of Chemistry, Central University of Haryana, Mahendergarh, 123031 Haryana India.

Deepak Kumar (D)

Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan, 173229 India.

Classifications MeSH